One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Compared with a cohort free of kidney disease, patients with primary nephrotic syndrome were nearly 20-times ...

– Gazyva versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 – – If approved, Gazyva could help children and young adults ...

Topline data were announced from a phase 3 study evaluating obinutuzumab in patients between 2 and 25 years of age with idiopathic nephrotic syndrome.

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

If approved, Gazyva/Gazyvaro could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease 1 INShore is the first global phase III study ...

– If approved, Gazyva could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease – – INShore is the first global Phase III study of a ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.